John Parkinson

This novel concept can benefit patients and clinicians alike by appropriately applying new technologies to identify bacteria more efficiently and decrease the time to optimal therapy.

Latest monkeypox updates from CDC and WHO.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.

The approval of the Spikevax vaccine was based on safety and efficacy data approximately 6 months after the second dose.

The relative risk reduction was 94% in patients 65 years of age or older in clinical trials.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP could boost users.

The data shows booster shots offer particularly strong protection against the variant.

Data from 5 trials presented at ID Week 2021 are promising for the investigational biotherapeutic.

The VRBPAC voted 16-2 against the booster dose because of unclear evidence regarding the need.

Would mark the first COVID-19 vaccine to gain full FDA approval.

IDSA and SHEA released 3 new evidence-based recommendations for treating CDI.

The company expects to file for FDA authorization for the 12-17 year old population in June.

The companies announce plans to submit a Biologics License Agreement for the mRNA-based vaccine.

In a 4000 person study, investigators find vaccinated individuals unlikely to transmit COVID-19.

The pandemic had an immediate effect on patient care, and in pivoting to adapt to the quarantine, some changes may have created potentially permanent ways to deliver health care.

Cabotegravir’s FDA breakthrough designation along with adaptive strategies being deployed are the biggest stories in HIV prevention this year.

Living longer because of antiretroviral therapy (ART), people with HIV (PWH) need to be counseled for age-related medical issues, and may also be eligible for newer ART. However, social determinants, stigma about the virus, and continuum of care issues remain challenges to many within the PWH population.

Experts weigh in on various reasons behind the United States' shortcoming in containing the pandemic.

AZD1222 demonstrated safety and immunogenicity across all adult age groups.

The goal is to begin delivering safe and effective COVID-19 vaccines to the Amerian people.

Findings of the trial on tocilizumab fall short.

The findings show 31.5% of pregnant women with COVID-19 are hospitalized compared to just 5.8% of nonpregnant women.

The therapy reduces death by 35% in patients with respiratory complications.

The drug reduces the time to improvement of flu symptoms in patients having at least 1 high-risk factor.